imeglimin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics 5483 775351-65-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • imeglimin
  • imeglimin hydrochloride
  • twymeeg
Imeglimin is a first-in-class oral agent which improves pancreatic beta-cell function and enhances insulin action in key tissues, including liver and skeletal muscle.
  • Molecular weight: 155.21
  • Formula: C6H13N5
  • CLOGP: -0.92
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 66.01
  • ALOGS: -1.52
  • ROTB: 0

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,ITK,MAP3K21,MAPK7,MARK4,NTRK2,PDK2,PRKDC,SIK2,STK33,TEK,TTK 25
kinase-selectivity-class GRK2 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
June 23, 2021 PMDA SUMITOMO DAINIPPON PHARMA Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Glycosylated haemoglobin increased 133.88 93.00 25 241 15537 90612644

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Glycosylated haemoglobin increased 144.79 63.28 29 225 12895 42608186

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Glycosylated haemoglobin increased 279.15 54.78 55 566 23564 110565114
Low density lipoprotein increased 73.67 54.78 16 605 10650 110578028
Lactic acidosis 68.89 54.78 24 597 92787 110495891
High density lipoprotein decreased 65.18 54.78 13 608 5720 110582958

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BX15 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Other blood glucose lowering drugs, excl. insulins
CHEBI has role CHEBI:35526 hypoglycemic agent

Related Drugs by ATC class:

A10BX Other blood glucose lowering drugs, excl. insulins 6 drugs
benfluorexmitiglinidenateglinidepramlintiderepaglinidetirzepatide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
UU226QGU97 UNII
2650481-44-8 SECONDARY_CAS_RN
C3501765 UMLSCUI
CHEBI:756996 CHEBI
CHEMBL4297514 ChEMBL_ID
24812808 PUBCHEM_CID
DB12509 DRUGBANK_ID
8969 INN_ID
C575881 MESH_SUPPLEMENTAL_RECORD_UI
D11807 KEGG_DRUG

Pharmaceutical products:

None